GoAI
Get started
Vicore Pharma Holding AB logo

Vicore Pharma Holding AB

VCRE

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$12.25

+$0.50 · +4.17%

Aug 21, 3:55 PM ET

VCRE company overview

Regular session · ET · Market data may be delayed.

Company profile

Company website

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. Its drug development programs include VP01, VP02, VP03, and VP04. The company was founded in 2000 sand is headquartered in Stockholm, Sweden.

Industry
Biotechnology
Sector
Healthcare
Headquarters
SE
CEO
Ahmed Mousa
Listed since
Jul 2, 2026
Employees
37

Market position

Volume
4.71K
0.17× average
Average volume
28.19K
Average daily volume
Market cap
3.52B USD
Beta
0.15
Market reference 1

Earnings

EPS beat rate
20%
1 beat, 4 misses, 0 met estimates
Average EPS surprise
-14.07%
5 comparable reports
Latest EPS result
-0.05
Estimate -0.04 · Miss by 24.39%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-0.05-0.07-0.1Q4 '24No estimateQ1 '25MissQ2 '25EstimateQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26Miss
Q4 2024, reported Nov 5, 2024: actual -0.053, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Feb 27, 2025: actual -0.046, estimate -0.032, surprise -42.95%, Miss. Q2 2025, reported May 6, 2025: actual —, estimate -0.044, surprise —, Comparison unavailable. Q4 2025, reported Nov 5, 2025: actual -0.053, estimate -0.052, surprise -3.06%, Miss. Q1 2026, reported Feb 27, 2026: actual -0.058, estimate -0.049, surprise -18.69%, Miss. Q2 2026, reported May 6, 2026: actual -0.041, estimate -0.051, surprise +18.75%, Beat. Q3 2026, reported Aug 21, 2026: actual -0.052, estimate -0.042, surprise -24.39%, Miss.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates492.26K340.43K188.61K36.79KQ1 '25No estimateQ2 '25BeatQ4 '25No estimateQ1 '26MissQ2 '26BeatQ3 '26No estimate
Q1 2025, reported Feb 27, 2025: actual 459K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 6, 2025: actual 89.28K USD, estimate 74.4K USD, surprise +20.00%, Beat. Q4 2025, reported Nov 5, 2025: actual 84.72K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Feb 27, 2026: actual 43.28K USD, estimate 86.56K USD, surprise -50.00%, Miss. Q2 2026, reported May 6, 2026: actual 63.23K USD, estimate 50.18K USD, surprise +26.00%, Beat. Q3 2026, reported Aug 21, 2026: actual 226.61K USD, estimate —, surprise —, Comparison unavailable.

VCRE peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research VCRE

research.disclaimer